Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 1262

1.

Prevalence of Carotid Artery Disease among Ambulatory Patients with Coronary Artery Disease.

Kazum S, Eisen A, Lev EI, Iakobishvili Z, Solodky A, Hasdai D, Kornowski R, Mager A.

Isr Med Assoc J. 2016 Feb;18(2):100-3.

2.

EFFICACY OF 5 MG AND 10 MG ROSUVASTATIN IN TYPE-2 DIABETES MELLITUS WITH HYPERCHOLESTEROALEMIA.

Ullah F, Afridi AK, Rahim F, ur Rahman S, Ashfaq M.

J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):564-8.

PMID:
26721008
3.

Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital.

Sangsawang T, Sriwijitkamol A.

Vasc Health Risk Manag. 2015 Nov 4;11:563-7. doi: 10.2147/VHRM.S92461. eCollection 2015.

4.

Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.

Asch DA, Troxel AB, Stewart WF, Sequist TD, Jones JB, Hirsch AG, Hoffer K, Zhu J, Wang W, Hodlofski A, Frasch AB, Weiner MG, Finnerty DD, Rosenthal MB, Gangemi K, Volpp KG.

JAMA. 2015 Nov 10;314(18):1926-35. doi: 10.1001/jama.2015.14850.

PMID:
26547464
5.

Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial.

Domanski MJ, Fuster V, Diaz-Mitoma F, Grundy S, Lloyd-Jones D, Mamdani M, Roberts R, Thorpe K, Hall J, Udell JA, Farkouh ME.

J Am Coll Cardiol. 2015 Oct 20;66(16):1828-36. doi: 10.1016/j.jacc.2015.08.857. Review.

PMID:
26483108
6.

Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.

Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, Oh J, Zimmerman CO, Hwang J, Abbara S, Plutzky J, Robbins G, Tawakol A, Hoffmann U, Grinspoon SK.

Lancet HIV. 2015 Feb;2(2):e52-63. doi: 10.1016/S2352-3018(14)00032-0. Epub 2015 Jan 9.

7.

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies.

Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, Rysz J, Toth PP, Muntner P, Mosteoru S, García-García HM, Hovingh GK, Kastelein JJ, Serruys PW; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.

BMC Med. 2015 Sep 18;13:229. doi: 10.1186/s12916-015-0459-4. Review.

8.

Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation.

Soucek F, Covassin N, Singh P, Ruzek L, Kara T, Suleiman M, Lerman A, Koestler C, Friedman PA, Lopez-Jimenez F, Somers VK.

Am J Cardiol. 2015 Nov 1;116(9):1443-6. doi: 10.1016/j.amjcard.2015.07.067. Epub 2015 Aug 14.

PMID:
26372211
9.

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.

Rosen JB, Ballantyne CM, Hsueh WA, Lin J, Shah AK, Lowe RS, Tershakovec AM.

Lipids Health Dis. 2015 Sep 4;14:103. doi: 10.1186/s12944-015-0075-5.

10.

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.

Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE–IVUS Investigators.

J Am Coll Cardiol. 2015 Aug 4;66(5):495-507. doi: 10.1016/j.jacc.2015.05.065.

PMID:
26227186
11.

Effect of Intensive Statin Therapy on Coronary High-Intensity Plaques Detected by Noncontrast T1-Weighted Imaging: The AQUAMARINE Pilot Study.

Noguchi T, Tanaka A, Kawasaki T, Goto Y, Morita Y, Asaumi Y, Nakao K, Fujiwara R, Nishimura K, Miyamoto Y, Ishihara M, Ogawa H, Koga N, Narula J, Yasuda S.

J Am Coll Cardiol. 2015 Jul 21;66(3):245-56. doi: 10.1016/j.jacc.2015.05.056.

PMID:
26184618
12.

Statin-induced coronary artery disease regression rates differ in men and women.

Puri R, Nissen SE, Nicholls SJ.

Curr Opin Lipidol. 2015 Aug;26(4):276-81. doi: 10.1097/MOL.0000000000000195. Review.

PMID:
26132419
13.

The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report.

Li YF, Feng QZ, Gao WQ, Zhang XJ, Huang Y, Chen YD.

BMC Cardiovasc Disord. 2015 Feb 14;15:6. doi: 10.1186/1471-2261-15-6. Review.

14.

Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients.

Bencsik P, Sasi V, Kiss K, Kupai K, Kolossváry M, Maurovich-Horvat P, Csont T, Ungi I, Merkely B, Ferdinandy P.

Eur J Clin Invest. 2015 Jul;45(7):692-701. doi: 10.1111/eci.12458. Epub 2015 Jun 1.

PMID:
25944577
15.

Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.

Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.

Atheroscler Suppl. 2015 May;18:163-9. doi: 10.1016/j.atherosclerosissup.2015.02.025.

PMID:
25936321
16.

Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease.

Thapa R, Sharma S, Jeevanantham V, Hu C, Myers T, Vacek JL, Dawn B, Gupta K.

J Clin Lipidol. 2015 Mar-Apr;9(2):241-6. doi: 10.1016/j.jacl.2014.11.006. Epub 2014 Dec 23.

PMID:
25911081
17.

Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.

Masuda J, Tanigawa T, Yamada T, Nishimura Y, Sasou T, Nakata T, Sawai T, Fujimoto N, Dohi K, Miyahara M, Nishikawa M, Nakamura M, Ito M.

Int Heart J. 2015 May 13;56(3):278-85. doi: 10.1536/ihj.14-311. Epub 2015 Apr 23.

18.

Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).

O'Brien EC, Simon DN, Roe MT, Wang TY, Peterson ED, Alexander KP.

Am J Cardiol. 2015 Jun 15;115(12):1655-60. doi: 10.1016/j.amjcard.2015.03.007. Epub 2015 Mar 23.

PMID:
25888303
19.

Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.

Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH; TNT Steering Committee and Investigators.

J Am Coll Cardiol. 2015 Apr 21;65(15):1539-48. doi: 10.1016/j.jacc.2015.02.017.

20.

Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.

Magee MF, Tamis-Holland JE, Lu J, Bittner VA, Brooks MM, Lopes N, Jacobs AK, Study Group B2.

Int J Endocrinol. 2015;2015:610239. doi: 10.1155/2015/610239. Epub 2015 Mar 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk